

# Contents

<b>Development of a Manufacturing Process for the Formation of a Nucleoside Drug Candidate</b> . . . . .	1
Fabrice Gallou	
<b>Development of Efficient Routes to Access C-Glycosides as SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes</b> . . . . .	29
Sébastien Lemaire and Didier Schils	
<b>Synthetic Routes to Sofosbuvir</b> . . . . .	51
Roland Barth, Christopher A. Rose, and Olga Schöne	
<b>Synthetic Challenges in the Assembly of Macrocyclic HCV NS3/NS4A Protease Inhibitors: The Case of BILN 2061 and Its Analogs</b> . . . . .	89
Youla S. Tsantrizos	
<b>Recent Progress in the Synthesis of Super-Statins</b> . . . . .	113
Zdenko Časar	
<b>Development of Synthetic Routes to Dolutegravir</b> . . . . .	187
Erwin Schreiner, Frank Richter, and Sven Nerding	
<b>Story of Eribulin Mesylate: Development of the Longest Drug Synthesis</b> . . . . .	209
Armin Bauer	
<b>Index</b> . . . . .	271